What do systematic reviews say?

All‐cause mortality · people with abnormal coagulation requiring a central venous catheter

All‐cause mortality ‐ not reported · ambulatory patients with multiple myeloma receiving immunomodulatory agents

All‐cause mortality ‐ not reported · adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy

All‐cause mortality ‐ not reported · people with haematological disorders undergoing intensive chemotherapy or stem cell transplantation

All‐cause mortality at 100 days post‐transplant · People undergoing stem cell transplant with malignant diseases

All‐cause mortality at 100 days post‐transplant · Patients undergoing stem cell transplant with malignant and non‐malignant diseases

All‐cause mortality at 100 days post‐transplant · Patients undergoing stem cell transplant with malignant and non‐malignant diseases

All‐cause mortality at 100 days post‐transplant · Patients undergoing stem cell transplant with malignant and non‐malignant diseases

All‐cause mortality at 100 days post‐transplant · Patients undergoing stem cell transplant with malignant and non‐malignant diseases

All‐cause mortality at 100 days post‐transplant · Patients undergoing stem cell transplant with malignant and non‐malignant diseases

All‐cause mortality up to 30 days ‐ not reported · patients undergoing non‐cardiac surgery/invasive procedures

All‐cause mortality up to 30 days ‐ not reported · patients undergoing non‐cardiac surgery/invasive procedures

All‐cause mortality up to 120 days · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19

All‐cause mortality up to 30 days after the procedure · thrombocytopenia

All‐cause mortality within 30 days of surgery – not reported · people with a low platelet count

All‐cause mortality within 30 days of surgery – not reported · people with a low platelet count